This study is trying to find out if adding a drug called Docetaxel to the usual treatment for prostate cancer helps stop the cancer from growing or spreading. Prostate cancer is a disease where cells in the prostate (a part of the male reproductive system) grow uncontrollably. The usual treatment is a hormone treatment called Androgen Deprivation Therapy (ADT) and an Androgen-Receptor Pathway Inhibitor (ARPI).

In this study, they are testing if adding Docetaxel, a chemotherapy drug, makes the treatment more effective for patients whose prostate-specific antigen (PSA) levels aren’t responding well. PSA is a protein made by the prostate, and high levels can be a sign of cancer.

• The study lasts between 6 to 12 months after starting ADT and ARPI therapy.
• Participants must be able to take Docetaxel and get regular check-ups.
• Patients will need to sign consent forms and use safe contraception if they can have children.